88
88
Mar 29, 2017
03/17
by
CNBC
tv
eye 88
favorite 0
quote 0
. >>> sanofi and regeneron scoring a win as the fda approved their new drug to treat eczema.he therapy could eventually bring in more than $3 billion in annual sales. the shares basically flat today in french trade for sanofi. >>> the fda also approving roche's multiple sclerosis drug putting the drug back on track after a three-month delay by regulators over manufacturing issues. >>> more stocks to watch. toshiba's nuclear unit westinghouse filing for chapter 11 bankruptcy after westinghouse faced billions of dollars in cost overruns and years-long delays at u.s. power projects. also a risk that toshiba may be de-listed from the tokyo stock exchange. >>> shares of dave and buster's falling today. the restaurant and arcade shares earnings fell short. they project weaker growth for 2017. this stock has been trading at record highs, so a lot of upside built into the stock. shares of sonic under pressure. the drive-in restaurant chain's revenues falling short of estimates. the company blaming a sluggish consumer environment and weather headwinds. if you look at it. consumer conf
. >>> sanofi and regeneron scoring a win as the fda approved their new drug to treat eczema.he therapy could eventually bring in more than $3 billion in annual sales. the shares basically flat today in french trade for sanofi. >>> the fda also approving roche's multiple sclerosis drug putting the drug back on track after a three-month delay by regulators over manufacturing issues. >>> more stocks to watch. toshiba's nuclear unit westinghouse filing for chapter 11...
482
482
Mar 29, 2017
03/17
by
KNTV
tv
eye 482
favorite 0
quote 0
. >> reporter: regeneron and its partner sanofi spent over $20 billion over many years creating something that's supposed to be a life changer for patients. calico cooper can keep performing following in the footsteps of her father, shock rocker, alice cooper. >> i am healthy and i am able to work and wear makeup, wear sunscreen and put on my favorite perfume. >> reporter: now unafraid to show the world who she really is. anne thompson, nbc news, tarrytown, new york. >>> still ahead tonight, is this the end of atm cards? the new way banks are letting you make cash withdrawals. and it's secure and lets you ditch your wallet with no swiping necessary. and the weather threat putting millions of americans at risk this evening. >>> we're back now with a new technology that could change the way you get cash from the bank and could mark the beginning of the end of atm cards. it's more secure for customers and more convenient for people worried about losing those debit cards. nbc news business correspondent jolene kent tells us how it works. >> reporter: heather quinlan's atm card number has been
. >> reporter: regeneron and its partner sanofi spent over $20 billion over many years creating something that's supposed to be a life changer for patients. calico cooper can keep performing following in the footsteps of her father, shock rocker, alice cooper. >> i am healthy and i am able to work and wear makeup, wear sunscreen and put on my favorite perfume. >> reporter: now unafraid to show the world who she really is. anne thompson, nbc news, tarrytown, new york....
71
71
Mar 29, 2017
03/17
by
CNBC
tv
eye 71
favorite 0
quote 0
. >>> sanofi's new drug to treat eczema will particular ket the product with regeneron. it will have a list price of $37,000 which is less of other products of the same kind. $37,000. that's pricey. the drug initially cost 50,000. maybe that's a bit of a discount. let's get back to politics. it's another major setback for francois fillon's presidential campaign. two weeks ago was put under formal investigation for paying his wife from public funds for work she did not do. yesterday his wife, penelope fillon was also put under formal investigation after being questioned by magistrates. >>> man well valls says he will vote for manuel macron in the presidential election. let's get out to claire. do you think valls will help macron more than he will help him since he comes from deeply unpopular socialist branch. >> that's the question, carolin. it's double sided this support from valls to macron. he has been fighting as to not continue the continuity of the fillon era. the former prime minister is more of a handicap for him than asset. on the radio this morning he said i tha
. >>> sanofi's new drug to treat eczema will particular ket the product with regeneron. it will have a list price of $37,000 which is less of other products of the same kind. $37,000. that's pricey. the drug initially cost 50,000. maybe that's a bit of a discount. let's get back to politics. it's another major setback for francois fillon's presidential campaign. two weeks ago was put under formal investigation for paying his wife from public funds for work she did not do. yesterday his...
63
63
Mar 24, 2017
03/17
by
BLOOMBERG
tv
eye 63
favorite 0
quote 0
sanofi in the mix as well. banks are bid this morning. look at credit suisse. i'm going to shifted over. where will move it on. there are the gainers. matt: that is very interesting. guy: we are rotating that. if you believe you are in a risk on environment, you buy the banks, you've got barclays, credit suisse, hsbc all trading higher, miners higher as well. the fact that see is trading up is an indicator. matt: absolutely. it lowered its capital buffer because of a settlement and as it boosted bonuses, certainly something bankers are watching. the u.s. health care bill is coming down to a high-stakes gamble with president trump sending it to a vote a day later than expected without knowing for sure he has enough support to pass it. the whole thing is being watched closely by investors because it is seen as a gauge on his mandate on his power in congress. joining us is yogesh dewan as well as mark cudmore in singapore. how important is this health care bill passage to the trump rally? yogesh: i think it is very important. it is a stepping stone for what could
sanofi in the mix as well. banks are bid this morning. look at credit suisse. i'm going to shifted over. where will move it on. there are the gainers. matt: that is very interesting. guy: we are rotating that. if you believe you are in a risk on environment, you buy the banks, you've got barclays, credit suisse, hsbc all trading higher, miners higher as well. the fact that see is trading up is an indicator. matt: absolutely. it lowered its capital buffer because of a settlement and as it...
147
147
Mar 29, 2017
03/17
by
CNBC
tv
eye 147
favorite 0
quote 0
sanofi and regeneron scoring a win as the fda approved a new drug to treat eczema.he therapy could bring in more than $3 billion in annual sales. >>> the fda also approving roche's multiple sclerosis drug. the green light puts the drug back on track after a three-month delay by regulators over manufacturing issues. meg tirrell has more on the pharma news at the bottom of the hour. >>> new economic data out from chi china paints a more worrying picture out of bay sing. we' bay jieijin beijing. we'll reveal those numbers next. . ♪ ♪ wanna get away? now you can with southwest fares as low as 59 dollars one-way. yes to low fares with nothing to hide. that's transfarency. kevin, meet yourkeviner. kevin kevin kevin kevin kevin kevin kevin kevin kevin trusted advice for life. kevin, how's your mom? life well planned. see what a raymond james financial advisor can do for you. . >>> welcome back. important data from china later this week, while our next guest expecting a strong read he's worrying about how big a price beijing is paying by projecting a stable growth. we're jo
sanofi and regeneron scoring a win as the fda approved a new drug to treat eczema.he therapy could bring in more than $3 billion in annual sales. >>> the fda also approving roche's multiple sclerosis drug. the green light puts the drug back on track after a three-month delay by regulators over manufacturing issues. meg tirrell has more on the pharma news at the bottom of the hour. >>> new economic data out from chi china paints a more worrying picture out of bay sing. we' bay...